DrugPatentWatch Database Preview
Drugs in Development Information for Defactinib
Development status for investigational drug Defactinib: Patents, clinical trial progress, indications
Defactinib is an investigational drug.
There have been 13 clinical trials for Defactinib.
The most recent clinical trial was a Phase 1 trial, which was initiated on September 1st 2013.
The most common disease conditions in clinical trials are Mesothelioma, Ovarian Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Verastem, Inc., Merck Sharp & Dohme Corp., and NHS Greater Glasgow and Clyde.
There are four US patents protecting this investigational drug and forty-two international patents.
Summary for Defactinib
| US Patents | 4 |
| International Patents | 42 |
| US Patent Applications | 16 |
| WIPO Patent Applications | 5 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2013-09-01) |
| Vendors | 45 |
Recent Clinical Trials for Defactinib
| Title | Sponsor | Phase |
|---|---|---|
| Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma | Merck Sharp & Dohme Corp. | Phase 2 |
| Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma | Verastem, Inc. | Phase 2 |
| Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
Clinical Trial Summary for Defactinib
Top disease conditions for Defactinib
Top clinical trial sponsors for Defactinib
US Patents for Defactinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Defactinib | See Pricing | Sulfonyl amide derivatives for the treatment of abnormal cell growth | Pfizer Inc (New York, NY) | See Pricing |
| Defactinib | See Pricing | Sulfonyl amide derivatives for the treatment of abnormal cell growth | Pfizer Inc (New York, NY) | See Pricing |
| Defactinib | See Pricing | Sulfonyl amide derivatives for the treatment of abnormal cell growth | See Pricing | |
| Defactinib | See Pricing | Methods and compositions for treating abnormal cell growth | Verastem, Inc. (Needham, MA) | See Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Defactinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Defactinib | Argentina | 066125 | 2027-04-18 | See Pricing |
| Defactinib | Australia | 2008240359 | 2027-04-18 | See Pricing |
| Defactinib | Brazil | PI0810411 | 2027-04-18 | See Pricing |
| Defactinib | Canada | 2684447 | 2027-04-18 | See Pricing |
| Defactinib | Chile | 2008001076 | 2027-04-18 | See Pricing |
| Defactinib | China | 101678215 | 2027-04-18 | See Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
